People: Organovo Holdings Inc (ONVO.PK)

ONVO.PK on OTC Markets Group

4.25USD
24 May 2013
Price Change (% chg)

$0.07 (+1.58%)
Prev Close
$4.18
Open
$4.29
Day's High
$4.34
Day's Low
$4.20
Volume
225,686
Avg. Vol
499,450
52-wk High
$10.90
52-wk Low
$1.49

Search Stocks

Summary

Name Age Since Current Position

Keith Murphy

 41 2012 Chairman of the Board, President, Chief Executive Officer

Barry Michaels

 63 2011 Chief Financial Officer, Corporate Secretary

Sharon Presnell

 44 2011 Executive Vice President - Research and Development, Chief Technology Officer

Michael Renard

 54 2012 Executive Vice President - Commercial Operations

Eric David

 41 2012 Chief Strategy Officer

Andras Forgacs

 36 2012 Director

Adam Stern

 49 2012 Director

Robert Baltera

 47 2012 Independent Director

James Glover

 61 2012 Independent Director
» Insider Trading

Biographies

Name Description

Keith Murphy

 Mr. Keith Murphy is Chairman of the Board, President, Chief Executive Officer of Organovo Holdings Inc. Mr. Murphy was formerly an employee of biotechnology company Alkermes, Inc., where he worked from July, 1993 to July, 1997 and played a role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen, Inc. in August, 1997 and developed several other novel formulation and device products. He has over 19 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen through July, 2007. He was previously Global Operations Leader for the development program in Amgen’s history, osteoporosis/bone cancer drug Prolia/Xgeva (denosumab). He holds a BS in Chemical Engineering from MIT, and is an alumnus of the UCLA Anderson School of Management.

Barry Michaels

 Mr. Barry D. Michaels is Chief Financial Officer, Corporate Secretary of Organovo Holdings Inc. Mr. Michaels was the Chief Financial Officer of Cardima, Inc., a publicly-traded medical device company (NASDAQ: CRDM), from July, 2003 through June, 2005, and thereafter a consultant to the company through January, 2008. Mr. Michaels has been an independent consultant to medical device and technology companies since 1997, and has more than 30 years of combined industry experience. Since January, 2008 and prior to joining the company, Mr. Michaels devoted his time to his consulting practice. In addition to his consulting practice, Mr. Michaels served as Chief Financial Officer of Lipid Sciences (NASDAQ: LIPD), a biotechnology company, from May, 2001 through January, 2003. Prior to joining Lipid Sciences, Mr. Michaels served as the Chief Financial Officer of IntraTherapeutics, Inc., an endovascular company, from March, 2000 until its acquisition by Sulzer Medica in May, 2001. Mr. Michaels received an MBA in finance from San Diego State University and is a graduate of the Executive Program at the University of California, Los Angeles.

Sharon Presnell

 Dr. Sharon Collins Presnell, Ph.D., is Executive Vice President - Research and Development, Chief Technology Officer of Organovo Holdings Inc. Dr. Presnell has over 15 years of experience in the leadership of product-focused R&D. As an Assistant Professor at the University of North Carolina from 1998 to 2001, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were out licensed for industrial applications. She joined Becton Dickinson & Co. (BD) in July, 2001 and played a key role in the early discovery and development of BD’s Discovery Platform and FACS CAP™ tools for the optimization of in vitro culture environments and flow cytometry-based characterization of cells. In her role at BD, she grew and led a multi-disciplinary team to establish feasibility for the Discovery Platform and FACS CAP in multiple therapeutic areas, including diabetes, and stewarded both technologies through revenue-generating commercial partnerships. Dr. Presnell joined Tengion, Inc. in February, 2007 as the Senior Vice President of Regenerative Medicine Research, a position that she held until joining the company in May 2011. At Tengion, Dr. Presnell was directly involved in the discovery and early development of Tengion’s Neo-Kidney Augment™ technology. Dr. Presnell holds a Ph.D. in Pathology from the Medical College of Virginia.

Michael Renard

 Mr. Michael Renard is Executive Vice President - Commercial Operations of Organovo Holdings, Inc. Mr. Renard has more than 29 years of experience in commercial operations, business development and sales and marketing for the life science industry. Since 1997, he has worked with Beckman Coulter holding various positions in program management, business operations and business development. He most recently was the vice president of marketing for North America commercial operations where he was responsible for achieving $2 billion in revenue across 11 product lines. Before Beckman Coulter, he was Vice President and General Manager in a start-up development stage incubator division of Sanofi, Inc. and Director of Corporate Accounts at Kallestad Diagnostics. He has an M.B.A from Rockhurst University and a B.A. in biology and chemistry from St. Olaf College.

Eric David

 Dr. Eric Michael David, Ph.D., is Chief Strategy Officer of Organovo Holdings, Inc. Dr. David was most recently Associate Partner at the consultancy McKinsey & Company, where he served private equity, pharmaceutical, biotech, diagnostic, and medical device clients to support pipeline and R&D strategy, as well as market entry strategy. Dr. David played a critical role in the commercial translation of 3D bioprinting as a founder and early director of Organovo, Inc. Prior to his time at McKinsey, Dr. David served as a freelance consultant to the Department of Health and Human Services in the use of genomic technologies for early detection of pathogens for public health preparedness. He completed his residency in Internal Medicine at New York Presbyterian Hospital, where he served as Assistant Chief Resident and received the Dick Bowman Award for scientific endeavor and dedication to patient care. He was also Assistant Professor at The Rogosin Institute and adjunct faculty at The Rockefeller University. He received his M.D. from Columbia University College of Physicians and Surgeons, his J.D. from Columbia University School of Law, and a B.A.in physics and fine arts from Amherst College. He is board certified in Internal Medicine and admitted to the Bar in New York State.

Andras Forgacs

 Mr. Andras Forgacs is Director of Organovo Holdings Inc. Mr. Forgacs has served as Chief Executive Officer of Modern Meadow, a private company focused on applying the latest advances in tissue engineering to develop cultured leather and meat products, since August 2011. Mr. Forgacs served as a Managing Director at Richmond Global, an international technology-focused venture fund from July, 2008 to January 2012. In his role at Richmond, Mr. Forgacs focuses on the day-to-day management of the fund and the sourcing of new investment opportunities. Prior to joining Richmond, beginning in November, 2005, he was a consultant in the New York office of McKinsey & Company advising global financial institutions, healthcare/pharmaceutical companies and private equity/venture capital firms. Mr. Forgacs began his career with Citigroup as an investment banker in the Financial Strategy Group in July, 1999, and helped found the client-facing E-commerce Group. Mr. Forgacs is a Kauffman Fellow with the Center for Venture Education and a Term Member with the Council on Foreign Relations. He holds an MBA from the Wharton School of Business and a Bachelor of Arts with honors from Harvard University.

Adam Stern

 Mr. Adam K. Stern is Director of Organovo Holdings Inc. He is the Chief Executive Officer of SternAegis Ventures, and has served as the Head of Private Equity Banking at Aegis Capital Corp. since November 2012. Mr. Stern has over 20 years of venture capital and investment banking experience focusing primarily on the technology and life science sectors of the capital markets. Prior to joining Aegis Capital, he managed the structured finance group of Spencer Trask Ventures, Inc. Mr. Stern joined Spencer Trask Ventures in September 1997 from Josephthal & Co., members of the New York Stock Exchange, where he served as Senior Vice President and Managing Director of Private Equity Marketing and held increasingly responsible positions from 1989 to 1997. He has been a licensed securities broker since 1987 and a General Securities Principal since 1991. Mr. Stern currently sits on the boards of various private companies and one other public company, InVivo Therapeutics Holdings Corp. (OTCBB:NVIV). Mr. Stern holds a Bachelor of Arts degree with honors from The University of South Florida in Tampa.

Robert Baltera

 Mr. Robert Baltera, Jr., is Independent Director of Organovo Holdings Inc. Most recently, Mr. Baltera was the Chief Executive Officer of Amira Pharmaceuticals, a position he held from July, 2007 through September, 2011. Amira was sold to Bristol-Myers Squibb in September, 2011 for $325 million in cash up front, plus additional milestone payments of up to $150 million. Mr. Baltera is a seasoned pharmaceutical industry executive who has acquired business and product management experience during his 17 years with biotech pioneer Amgen, beginning November, 1990. In his role at Amira Pharmaceuticals, he was instrumental in focusing the company’s development efforts, strengthening and developing its pipeline and forging key collaborations with partners such as GlaxoSmithKline. Before becoming Amira’s CEO, he held a number of senior management positions at Amgen, the last being Vice President of Corporate and Contract Manufacturing. He served as Amgen’s team leader responsible for the approval of Kineret™ in rheumatoid arthritis. Mr. Baltera has an MBA from the Anderson School at UCLA and earned his bachelor’s degree in microbiology and a master’s degree in genetics from The Pennsylvania State University.

James Glover

 Mr. James T. Glover is Independent Director of Organovo Holdings, Inc. Mr. Glover was the Senior Vice President, Operations and Chief Financial Officer of Anadys Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company acquired by Hoffmann-La Roche Inc., from 2006 to 2009. From 1989 to 2006, he was employed by Beckman Coulter, Inc., a biomedical testing instruments company, most recently serving as Senior Vice President and Chief Financial Officer. Mr. Glover served as a director of Varian, Inc., a publicly-traded company purchased by Agilent Technologies, and was Varian’s audit committee chairman. He currently serves as a director for a non-profit corporation. Mr. Glover received his B.S. in accounting from California State Polytechnic University and his M.B.A. from Pepperdine University. Mr. Glover is also a certified public accountant.

Basic Compensation

Name Fiscal Year Total

Keith Murphy

 677,347

Barry Michaels

 1,785,170

Sharon Presnell

 616,832

Michael Renard

 958,328

Eric David

 973,114

Andras Forgacs

 --

Adam Stern

 --

Robert Baltera

 --

James Glover

 --
As Of 30 Dec 2012

Options Compensation

Name Options Value

Keith Murphy

 0 0

Barry Michaels

 0 0

Sharon Presnell

 0 0

Michael Renard

 0 0

Eric David

 0 0

Andras Forgacs

 0 0

Adam Stern

 0 0

Robert Baltera

 0 0

James Glover

 0 0

Insider Trading

Name Shares Traded Price

MURPHY KEITH

 24,690 $4.59

MICHAELS BARRY D

 10,000 $0.80

BALTERA ROBERT JR

 25,000 $0.80

MICHAELS BARRY D

 79,687 $2.10

MURPHY KEITH

 200,000 $0.00

MICHAELS BARRY D

 750,000 $0.00

PRESNELL SHARON COLLINS

 224,064 $0.08

MICHAELS BARRY D

 10,000 $1.00
» Full list on Insider Trading
Search Stocks